E iv F e C

dio com act for M pa car ge va Four of these procedures were reoperations. Intraopera-tive aprotinin was used in all patients. All patients underwent standard heparinization (300 IU/kg) before cardiopulmonary bypass and reversal with protamine. R dia plo for pla rFV 120 op rFV mL cal dru tio logic or cardiovascular complications. Conclusions. When used as rescue therapy for intracta-ble hemorrhage after cardiovascular surgery, rFVIIa may be effective in promoting hemostasis, preventing reex-plo In tio pro mo pa pro ter pro de tive in all cases. Activated recombinant factor VII (rFVIIa) (NovoSeven, NovoNordisk, Copenhagen, Denmark) has been shown to ha the rha exp for ag siv ab M Fro tre va ha op these procedures were reoperations. Aspirin (81 mg) was administered the day before surgery in all patients undergoing coronary artery bypass graf